PACIFIC BIOSCIENCES OF CALIFORNIA (PACB)
Health Care · Life Sciences Tools & Services / Genomic Sequencing · NASDAQ
Pacific Biosciences provides high-accuracy, long-read genomic sequencing solutions that enable researchers and clinicians to solve complex genetic challenges.
What PACIFIC BIOSCIENCES OF CALIFORNIA does
Pacific Biosciences designs, develops, and manufactures advanced sequencing solutions based on HiFi long-read sequencing technology. The company serves academic research institutions, clinical laboratories, pharmaceutical companies, and agricultural organizations with products addressing human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and emerging genomic applications. PacBio's systems are designed to provide the most complete and accurate view of genomes, transcriptomes, and epigenomes to resolve genetically complex problems.
Themes: Long-read genomic sequencing, Clinical genomics / whole-genome sequencing, Rare disease diagnosis, Genomics research tools, Precision medicine / genetic testing, Agricultural genomics, Oncology genomics, AI-assisted genomic data interpretation
Fundamentals
- Price$1.35 as of 2026-08-21 close
- Market cap$420M as of 2026-08-21
- 1-year return+7.1% 2025-08-21 close $1.26 → 2026-08-21 close $1.35
- P/En/a negative earnings
- Net margin-82.5% as of 2026-08-24
- Gross margin+39.2% as of 2026-08-24
- ROE-488.4% as of 2026-08-24
- Debt / equity272.23 as of 2026-08-24
- Revenue growth (YoY)+2.0% as of 2026-08-24
- Revenue CAGR (3y)-6.9% SEC XBRL
- Beta2.33 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How PACB compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How PACIFIC BIOSCIENCES OF CALIFORNIA looks technically
PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) is trading 19.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 94 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day low about 8 trading days ago. It is 50.5% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 19.0% below its 200-day average, the long-term trend line — a long-term downtrend | -19.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.40 | $1.40 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.67 | $1.67 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 94 trading days ago — a "death cross", a bearish long-term signal | 94 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 21.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 53.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($1.07 to $1.47) — its "stochastic" reading is 70 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 70.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $2.73 | $2.73 |
|---|---|---|
| From the 52-week high | it is 50.5% below its 52-week high (its highest price of the past year) | -50.5% |
| Above the 52-week low | it is 26.2% above its 52-week low (its lowest price of the past year) | +26.2% |
| Below the 52-week high | it is 50.5% below its highest point of the past year | 50.5% |
| Since a 20-day breakout | it made a new 20-day low about 8 trading days ago | 8 sessions |
| Since a 55-day breakout | it made a new 55-day low about 8 trading days ago | 8 sessions |
| All-time high | its highest closing price on record is $53.69 (set on 2021-02-11) | $53.69 |
| Given back of the 52-week move | over the past year its closes ranged ($1.11 to $2.67), and it has recovered roughly a quarter of its fall from last year’s high — 15% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.07 to $2.12. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 15.4% |
| From the all-time high | it is 97.5% below its all-time high | -97.5% |
| Nearest price level | it is sitting right on a support level at $1.34 — a price it turned at twice since 2025-07-18, most recently on 2025-09-19. Since 2024-08-21 it has 6 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.4% |
| All-time low | its lowest closing price on record is $0.8511 (set on 2025-05-28) | $0.8511 |
| Above the all-time low | it is 58.6% above its all-time low | +58.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 57th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1008 between its high and its low — about 7.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1008 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.03 and $1.51 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.03 – $1.27 – $1.51 |
| Typical daily range (% of price) | its price moves about 7.5% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.5% |
| Stretch from the 200-day average | it is trading 3.2 daily ranges below its 200-day average price (19.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.04× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.8% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.8% |
|---|---|---|
| Open gap | it gapped 5.3% above the previous close 2 sessions ago and has not traded back through the level it left behind at 1.14 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +5.3% |
| Gap filled | a 2.1% gap down opened on 2026-08-10 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 9 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 5.9 percentage points (the stock lost 3.6% while the market gained 2.3%) | -5.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 4.9 percentage points (the stock gained 8.0% while the market gained 3.1%) | +4.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 27.2 percentage points (the stock lost 16.1% while the market gained 11.1%) | -27.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 13.3 percentage points (the stock gained 7.1% while the market gained 20.5%) | -13.3% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.8% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 8.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -7.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 16% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $1.60 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -15.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 13% above the average price paid since it last reported on 2026-08-05 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $1.20 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +12.7% |
Price levels it has turned at before
PACB last closed at $1.35 on 2026-08-21. Since 2024-08-21 it has turned at 6 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.34 | Support | 0.4% below the last close | turned there twice · 2025-07-18 to 2025-09-19 |
| $1.37 | Resistance | 1.5% above the last close | turned there twice · 2025-03-24 to 2025-10-10 |
| $1.41 | Resistance | 4.3% above the last close | turned there four times · 2024-10-10 to 2026-04-29 |
| $1.27 | Support | 5.9% below the last close | turned there twice · 2024-09-05 to 2025-02-12 |
| $1.23 | Support | 9.1% below the last close | turned there twice · 2025-05-08 to 2026-03-27 |
| $1.50 | Resistance | 11.0% above the last close | turned there five times · 2024-11-19 to 2026-07-30 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · lagging the market · Left an unfilled gap (5%+ in the last week) · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.00 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$2.29 range $1.25 – $3.00; median $2.50
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PACB
- Consensus EPS estimate-$0.1298 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Unprofitable operations with -80.34% net margin; company is burning cash and dependent on capital access to fund R&D and growth initiatives.","Competitive pressure from established players like Illumina with significantly greater scale, resources, and market share in DNA sequencing.","Clinical adoption risk: success hinges on broad uptake of HiFi sequencing in laboratory-developed tests and clinical settings, which remains unproven at scale."]
What changed in the latest 10-Q
AI-assisted comparison of PACB's 10-Q filed 2026-05-08 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-08) references '2025 Annual Report filed with the U.S. Securities and Exchange Commission...on February 25, 2026' whereas older filing (2025-11-06) references '2024 Annual Report filed...on March 17, 2025'
- Newer filing adds specific mention of 'SPRQ-Nx chemistry' (versus 'SPRQ chemistry' in older filing)
- Newer filing adds strategic objective detail: 'Expand the capabilities of the Vega benchtop platform to broaden our market reach. We plan to enable faster run times and enhanced user experience through software improvements'
- Newer filing adds: 'Progress our clinical strategy to improve outcomes and create durability' with specific mention of 'in the Americas, where we continue to aggressively shift our strategy to clinical and commercial accounts where we believe the funding dynamics are more favorable'
- Newer filing adds strategic objective: 'Advance data-driven interpretation through scalable HiFi datasets and analytics' including reference to 'HiFi Solves Global Consortium'
- Newer filing reports Q1 2026 three-month results (March 31, 2026) with revenue of $37.2M, gross profit of $12.8M, operating loss of $8.4M, and cash/investments of $276.0M
- Newer filing reports litigation settlement expenses of $15.4 million in three months ended March 31, 2026
- Removed:
- Older filing (2025-11-06) contains reference to Nature Methods recognition of long-read sequencing as 'method of the year' for 2022, which is removed in newer filing
- Older filing references 'SMRT ® technology' in strategic context; newer filing does not include this trademark reference in comparable section
- Older filing lists 'four activities' for 2025 strategic objectives; newer filing lists 'five activities' for 2026 objectives
- Older filing reports Q3 2025 nine-month results (September 30, 2025); newer filing reports different period (Q1 2026 three-month results)
- Reworded:
- Older filing: 'Our products and technology, which include our HiFi long-read sequencing technology' changed to newer filing: 'Our products and technology, which primarily consist of our HiFi long-read sequencing systems'
- Older filing lists first objective as 'Enabling the full-scale release of the Vega benchtop platform'; newer filing addresses Vega as second objective with different scope and emphasis
- Older filing: 'Accelerating samples onto the Revio platform via SPRQ chemistry' changed to newer filing: 'Accelerate samples onto the Revio platform through SPRQ-Nx chemistry and application kits' with additional emphasis on cost reduction and efficiency
- Older filing references 'sub-$500 HiFi genome' metric; newer filing does not include this specific cost metric
- Older filing: objective order and emphasis differs; newer filing reorganizes four objectives into five with different strategic priorities
- Notes:
- The two filings cover different fiscal periods (Q3 2025 nine-month results versus Q1 2026 three-month results), so some financial metric changes reflect period differences rather than operational changes
- Text truncation in older filing's operating loss discussion prevents full comparison of that section
- Different fiscal year references (2025 Annual Report vs. 2024 Annual Report) reflect normal progression between filings
Risk Factors
- Added:
- Added risk factor in Summary section: 'the impact of the disposition of assets related to our short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies could have on our business, financial condition and results of operations' (filed 2026-05-08)
- Removed:
- Removed reference to 'Onso, our SBB short-read platform' commercial shipments in 2023 from the 'Risks Related to Our Business' section (filed 2025-11-06)
- Reworded:
- Changed 'the impact of tariffs recently imposed by the U.S. government and its trading partners in response' to 'the impact of tariffs recently threatened or imposed by the U.S. government or its trading partners in response' in Summary Risk Factors (filed 2026-05-08)
- Removed bullet point text 'complete the scientific and technical validation of new products on our currently expected timeline or at all; deliver our future products in a timely manner to our customers; grow our market share by marketing and selling our products for new and addition' at end of Risks Related to Our Business section appears truncated in newer filing (filed 2026-05-08)
- Notes:
- The newer filing text appears truncated at the end of the provided excerpt, making full comparison of subsequent risk factor details not fully assessable
- The removal of Onso references aligns with the new risk factor addition regarding 'disposition of assets related to short-read DNA sequencing technology,' suggesting a business transaction occurred between filings
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 1 sell ($120813) — 1 selling insider
Most recent open-market transaction: 2026-04-01. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PACB's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding PACB as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 72,013,967
- Reported value $95,058,436
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
PACB had 49,004,841 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PACB had 15.8% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.35 days to cover at the same settlement.
- Reported short interest (shares) 49,004,841
- Short interest (% of shares outstanding) 15.8%
- Prior settlement (shares) 46,237,636
- Reported change 5.98%
- Days to cover (reported) 7.35
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Illumina (ILMN)
- Oxford Nanopore Technologies (ONT.L)
- Thermo Fisher Scientific (TMO)
- 10x Genomics (TXG)
- BGI Group
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PACB vs…
Frequently asked questions
What does PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) do?
Pacific Biosciences designs, develops, and manufactures advanced sequencing solutions based on HiFi long-read sequencing technology. The company serves academic research institutions, clinical laboratories, pharmaceutical companies, and agricultural organizations with products addressing human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and emerging genomic applications.
What sector is PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) in?
PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) is classified in the Health Care sector. Its industry is Life Sciences Tools & Services / Genomic Sequencing. It trades on NASDAQ.
Who are PACIFIC BIOSCIENCES OF CALIFORNIA's (PACB) competitors?
Notable peers of PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) include Illumina, Oxford Nanopore Technologies, Thermo Fisher Scientific, 10x Genomics and BGI Group. This peer set is informational only — not financial advice.
Is PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) overbought or oversold right now?
PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PACB come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.